Results from the clinical trial at Texas A&M indicate the treatment could be useful in treating glioblastoma, an aggressive form of brain cancer found in humans.
A new publication explains the novel science behind the first molecular therapeutic for the rare neurogenetic disorder to advance into clinical development.